title: Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02.
abstract: OBJECTIVE
  Diabetes is associated with lower risk of prostate cancer. Most men with diabetes are obese, and obesity is associated with greater prostate cancer mortality. Whether diabetes influences outcomes after prostate cancer diagnosis is unknown.
  
  
  METHODS
  We assessed the relationship between prevalent diabetes and mortality using data from Radiation Therapy Oncology Group Protocol 92-02, a large randomized trial of men (N = 1,554) treated with radiation therapy and short-term versus long-term adjuvant goserelin for locally advanced prostate cancer. Regression and proportional hazard models were performed to evaluate relationships between prevalent diabetes and all-cause mortality, prostate cancer mortality, and non-prostate cancer mortality. Covariates included age, race, tumor stage, Gleason score, prostate-specific antigen, weight, and treatment arm.
  
  
  RESULTS
  There were a total of 765 deaths; 210 (27%) were attributed to prostate cancer. In univariate analyses, prevalent diabetes was associated with greater all-cause mortality and non-prostate cancer mortality but not prostate cancer mortality. After controlling for other covariates, prevalent diabetes remained significantly associated with greater all-cause mortality and non-prostate cancer mortality (hazard ratio [HR] = 2.12; 95% CI, 1.69 to 2.66; P < .0001) but not prostate cancer mortality (HR = 0.80; 95% CI, 0.51 to 1.25; P = .34). In contrast, weight was associated with greater prostate cancer mortality (HR = 1.77; 95% CI, 1.22 to 2.55; P = .002) but not all-cause or non-prostate cancer mortality.
  
  
  CONCLUSIONS
  Weight but not prevalent diabetes is associated with greater prostate cancer mortality in men receiving combined modality treatment for locally advanced disease. These observations suggest that the association between obesity and greater prostate cancer mortality is mediated by mechanism(s) other than the characteristic metabolic alterations of diabetes.
authors.affiliation: Department of Radiation Oncology, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA 02114, USA. smith.matthew@mgh.harvard.edu
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Smith
authors.forename: Kyounghwa
authors.initials: K
authors.lastname: Bae
authors.forename: Jason A
authors.initials: JA
authors.lastname: Efstathiou
authors.forename: Gerald E
authors.initials: GE
authors.lastname: Hanks
authors.forename: Miljenko V
authors.initials: MV
authors.lastname: Pilepich
authors.forename: Howard M
authors.initials: HM
authors.lastname: Sandler
authors.forename: William U
authors.initials: WU
authors.lastname: Shipley
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000401:mortality*; D017273:Goserelin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011878:Radiotherapy
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017273:Goserelin
references.citation: Cancer. 2006 Aug 1;107(3):631-9
references.pmid: 16802288
references.citation: J Clin Epidemiol. 2004 Oct;57(10):1096-103
references.pmid: 15528061
references.citation: J Clin Oncol. 2003 Nov 1;21(21):3972-8
references.pmid: 14581419
references.citation: Cancer Causes Control. 2005 Sep;16(7):789-97
references.pmid: 16132789
references.citation: Eur J Cancer. 2005 Dec;41(18):2887-95
references.pmid: 16243513
references.citation: Diabetes Care. 2007 Jan;30 Suppl 1:S42-7
references.pmid: 17192378
references.citation: Nat Genet. 2007 Aug;39(8):977-83
references.pmid: 17603485
references.citation: JAMA. 2005 Sep 14;294(10):1255-9
references.pmid: 16160134
references.citation: Ann Intern Med. 2007 Aug 7;147(3):149-55
references.pmid: 17576993
references.citation: J Clin Oncol. 2006 Sep 20;24(27):4448-56
references.pmid: 16983113
references.citation: J Natl Cancer Inst. 2007 Dec 5;99(23):1793-800
references.pmid: 18042933
references.citation: J Urol. 2005 Sep;174(3):919-22
references.pmid: 16093988
references.citation: Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6889-94
references.pmid: 16203779
references.citation: Epidemiol Rev. 2007;29:88-97
references.pmid: 17478439
references.citation: Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2056-62
references.pmid: 17119028
references.citation: Diabetes Care. 2006 Jun;29(6):1263-8
references.pmid: 16732006
references.citation: J Clin Oncol. 2004 Feb 1;22(3):439-45
references.pmid: 14691120
references.citation: Cancer. 2007 Dec 15;110(12):2691-9
references.pmid: 17999404
references.citation: J Chronic Dis. 1974 Sep;27(7-8):365-75
references.pmid: 4612056
references.citation: Diabetes Care. 1998 Jul;21(7):1138-45
references.pmid: 9653609
references.citation: J Clin Oncol. 2004 Feb 1;22(3):446-53
references.pmid: 14691122
references.citation: Obes Res. 1998 Sep;6 Suppl 2:51S-209S
references.pmid: 9813653